Puma Biotechnology, Inc.
PBYI
$3.01
-$0.03-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.68% | -2.19% | 6.30% | -4.77% | -3.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.68% | -2.19% | 6.30% | -4.77% | -3.59% |
| Cost of Revenue | 6.71% | 2.75% | 35.53% | 8.43% | 4.74% |
| Gross Profit | 1.23% | -3.98% | -2.98% | -8.86% | -6.29% |
| SG&A Expenses | -14.17% | -10.24% | -14.14% | -9.05% | -5.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.28% | -1.42% | 3.58% | -1.89% | -0.60% |
| Operating Income | 40.03% | -6.91% | 27.71% | -26.76% | -21.37% |
| Income Before Tax | 93.35% | 6.29% | 441.16% | 677.24% | 207.78% |
| Income Tax Expenses | -628.11% | -670.45% | 69.44% | 93.81% | 104.60% |
| Earnings from Continuing Operations | 147.59% | 40.23% | 525.26% | 457.52% | 219.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 147.59% | 40.23% | 525.26% | 457.52% | 219.91% |
| EBIT | 40.03% | -6.91% | 27.71% | -26.76% | -21.37% |
| EBITDA | 27.62% | -5.12% | 20.72% | -16.72% | -13.50% |
| EPS Basic | 137.93% | 34.91% | 537.28% | 439.42% | 202.04% |
| Normalized Basic EPS | 79.21% | -0.52% | 63.31% | -33.27% | -27.70% |
| EPS Diluted | 145.34% | 37.38% | 569.02% | 387.62% | 207.75% |
| Normalized Diluted EPS | 80.15% | -0.30% | 62.87% | -34.10% | -28.23% |
| Average Basic Shares Outstanding | 3.12% | 3.22% | 3.41% | 3.69% | 3.82% |
| Average Diluted Shares Outstanding | 2.89% | 2.55% | 3.03% | 3.55% | 4.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |